Literature DB >> 1986620

The effect of tetracycline on levels of oral contraceptives.

A A Murphy1, H A Zacur, P Charache, R T Burkman.   

Abstract

Despite the widespread use of tetracycline for treatment of dermatologic disorders and sexually transmitted diseases, the pharmacodynamics of oral contraceptive use in the presence of tetracycline has not been studied. Seven normal women ingested an oral contraceptive containing ethinyl estradiol 35 micrograms and norethindrone 1 mg in the follicular phase of the menstrual cycle. On day 0 baseline ethinyl estradiol and norethindrone levels were obtained at 0, 1/2, 3/4, 1, 2, 4, 12, and 24 hours after oral contraceptive administration. On day 1 tetracycline 500 mg was given orally every 6 hours while the oral contraceptive was continued. Tetracycline, ethinyl estradiol, and norethindrone levels were determined at the same time intervals as on day 0. Oral contraceptive and tetracycline were continued for up to 10 days, and additional concentrations of ethinyl estradiol, norethindrone, and tetracycline were determined between days 5 and 10. Four additional normal women ingested tetracycline for 5 to 10 days. Tetracycline levels were determined at the time intervals noted above on day 1 and days 5 to 10. No significant decrease in plasma ethinyl estradiol or norethindrone concentration was seen with either short-term (24 hours) or long-term (5 to 10 days) ingestion of tetracycline. Similarly, levels of tetracycline do not significantly decrease with ingestion of a low-dose oral contraceptive.

Entities:  

Keywords:  Antibiotics; Clinical Research; Contraception; Contraceptive Agents, Estrogen--analysis; Contraceptive Agents, Female--analysis; Contraceptive Agents, Progestin--analysis; Contraceptive Agents--analysis; Contraceptive Methods; Demographic Factors; Drug Interactions; Drugs; Ethinyl Estradiol--analysis; Examinations And Diagnoses; Family Planning; Laboratory Examinations And Diagnoses; Norethindrone--analysis; Oral Contraceptives; Population; Population Dynamics; Research Methodology; Time Factors; Treatment

Mesh:

Substances:

Year:  1991        PMID: 1986620     DOI: 10.1016/0002-9378(91)90617-z

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

1.  A randomized controlled trial of subantimicrobial-dose doxycycline to prevent unscheduled bleeding with continuous oral contraceptive pill use.

Authors:  Bliss Kaneshiro; Alison Edelman; Nichole E Carlson; Mark Nichols; Marci Messerle Forbes; Jeffrey Jensen
Journal:  Contraception       Date:  2011-09-28       Impact factor: 3.375

2.  Antibiotic and oral contraceptive drug interactions: Is there a need for concern?

Authors:  G G Zhanel; S Siemens; K Slayter; L Mandell
Journal:  Can J Infect Dis       Date:  1999-11

Review 3.  Interactions between oral contraceptives and antifungals/antibacterials. Is contraceptive failure the result?

Authors:  E Weisberg
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

Review 4.  Oral contraceptives. Are drug interactions of clinical significance?

Authors:  G M Shenfield
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

5.  Profiling and hormonal therapy for acne in women.

Authors:  Sangita Ghosh; Soumik Chaudhuri; Vijay Kumar Jain; Kamal Aggarwal
Journal:  Indian J Dermatol       Date:  2014-03       Impact factor: 1.494

6.  Safety and efficacy of doxycycline in the treatment of rosacea.

Authors:  Sheila Valentín; Adisbeth Morales; Jorge L Sánchez; Abimael Rivera
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-08-12

7.  Survey of pharmacists and physicians on drug interactions between combined oral contraceptives and broad-spectrum antibiotics.

Authors:  Kelly P Masters; Beth M Carr
Journal:  Pharm Pract (Granada)       Date:  2009-03-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.